Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 282.915 USD -0.47% Market Closed
Market Cap: 19.9B USD

Net Margin

9.8%
Current
Declining
by 1.8%
vs 3-y average of 11.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.8%
=
Net Income
$246.2m
/
Revenue
$2.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.8%
=
Net Income
$246.2m
/
Revenue
$2.5B

Peer Comparison

Country Company Market Cap Net
Margin
US
Insulet Corp
NASDAQ:PODD
20B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
210.8B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
186.6B USD
Loading...
US
Stryker Corp
NYSE:SYK
138B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
136.3B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
128B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.7B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
48.8B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55.7B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49.3B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
66th
Based on 15 072 companies
66th percentile
9.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Insulet Corp
Glance View

Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.

PODD Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
9.8%
=
Net Income
$246.2m
/
Revenue
$2.5B
What is Insulet Corp's current Net Margin?

The current Net Margin for Insulet Corp is 9.8%, which is below its 3-year median of 11.5%.

How has Net Margin changed over time?

Over the last 3 years, Insulet Corp’s Net Margin has increased from 1.4% to 9.8%. During this period, it reached a low of 0% on Mar 31, 2023 and a high of 21.2% on Sep 30, 2024.

Back to Top